The Infection That Won’t Quit
Anyone who has experienced chronic Lyme disease knows the pattern. The acute infection is treated — sometimes with antibiotics, sometimes with frequencies — and the spirochetes appear to be addressed. But the fatigue persists. The sinus problems linger. The brain fog refuses to lift. The flu-like symptoms cycle endlessly.
The reason, in many cases, is mycoplasma.
Mycoplasma co-infections are among the most underdiagnosed and undertreated components of the Lyme disease complex. They are the primary reason why many people with Lyme continue to feel sick long after the Borrelia spirochetes have been addressed. Understanding and eliminating mycoplasma is essential for anyone dealing with chronic Lyme and its cascading effects on long-term health — including cognitive decline and neurodegeneration.
What Are Mycoplasma?
Mycoplasma are the smallest known free-living organisms — sitting at the boundary between bacteria and viruses in terms of size and complexity. They are unique among bacteria for one critical reason: they lack a cell wall. This single characteristic makes them exceptionally difficult to treat and extraordinarily persistent.
Why the Lack of a Cell Wall Matters
Most antibiotics, including penicillin and its derivatives, work by attacking bacterial cell walls. Since mycoplasma have no cell wall, these antibiotics are completely ineffective against them. This means that standard Lyme disease antibiotic protocols, which target the cell-walled Borrelia spirochetes, do nothing to address mycoplasma co-infections. The spirochetes may be eliminated while the mycoplasma remain untouched — continuing to cause symptoms that are attributed to “post-treatment Lyme disease syndrome” when they are actually an ongoing, unaddressed infection.
How Mycoplasma Cause Chronic Symptoms
Mycoplasma are parasitic organisms that attach to and invade human cells, living off the host cell’s nutrients and energy resources. They commonly attach to red blood cells, siphoning energy and reducing oxygen delivery throughout the body. This is visible under dark-field microscopy as small spherical forms attached to red blood cells — a hallmark observation that the Frequency Research Foundation has documented extensively.
The energy depletion caused by mycoplasma attachment to red blood cells explains many of the persistent symptoms of chronic Lyme: the crushing fatigue, the excessive need for sleep, the inability to recover normal energy levels despite treatment of the primary spirochete infection.
Mycoplasma also trigger chronic immune activation. The immune system recognizes the mycoplasma as foreign but cannot effectively eliminate them due to their ability to invade cells and modify their surface proteins. This creates a perpetual inflammatory state — the body fighting an infection it cannot resolve — which produces the ongoing flu-like symptoms, joint pain, and malaise characteristic of chronic Lyme.
Mycoplasma in the Lyme Disease Complex
Lyme disease is rarely a single-organism infection. The ticks that transmit Borrelia burgdorferi (the Lyme spirochete) frequently carry multiple co-infections, and the resulting illness is more accurately described as a complex of interacting organisms.
The Key Players
The Lyme disease complex typically involves Borrelia spirochetes as the primary infection, which produce the most immediately disabling neurological and joint symptoms. Mycoplasma species, particularly Mycoplasma fermentans, serve as persistent co-infections that drive chronic fatigue and immune dysfunction. Various viruses contribute to immune suppression and neurological symptoms. Fungal organisms create additional immune burden. The interactions between these organisms are synergistic — each one makes the others more difficult to eliminate and more damaging to the host.
Why Addressing Spirochetes Alone Is Not Enough
Most conventional Lyme disease treatment focuses exclusively on eliminating Borrelia spirochetes with antibiotics. As Dr. Jeff Sutherland has observed in clinical practice, the spirochetes can be addressed relatively quickly with targeted frequencies — often in a matter of hours. However, the more difficult organisms are the viruses, the fungi, and above all the mycoplasma.
The mycoplasma are particularly challenging because they are often infected with nanobacteria — organisms within organisms. Eliminating mycoplasma therefore triggers a nanobacteria Herxheimer reaction as the secondary organisms are released. The primary symptom of nanobacteria infection is the need for excessive amounts of sleep, which is commonly seen in people with chronic Lyme infections and is often mistakenly attributed to the Lyme itself rather than to the co-infection within the co-infection.
This layered complexity is why a systematic approach is essential. At the Frequency Research Foundation, Dr. Jeff Sutherland’s research has focused on systematically disassembling mycoplasma with frequencies that target various parts of the organism and disperse the DNA. There are multiple mycoplasma strains in the Lyme complex, and untangling them all is a nontrivial task that requires careful, sequential treatment.
The Scale of the Problem
The prevalence of pathogenic mycoplasma in the general population is far greater than most people realize. Of the approximately 200 known species of mycoplasma, most are innocuous. However, four or five species are pathogenic to humans, and these have become increasingly widespread.
Widespread Infection
Research from multiple sources suggests that pathogenic mycoplasma now infect a significant portion of the population. Dr. Shyh-Ching Lo, a senior researcher at the Armed Forces Institute of Pathology and one of America’s leading mycoplasma researchers, has documented the connection between Mycoplasma fermentans and numerous chronic diseases. Dr. Lo holds a patent on Mycoplasma fermentans extracted from AIDS patients, and his research links this organism to chronic fatigue syndrome, fibromyalgia, and multiple other conditions.
Dr. Charles Engel of the US National Institutes of Health stated at an NIH meeting on February 7, 2000: “I am now of the view that the probable cause of chronic fatigue syndrome and fibromyalgia is the mycoplasma.”
According to Dr. Lo’s research, pathogenic mycoplasma have been implicated in AIDS, cancer, chronic fatigue syndrome, Crohn’s colitis, type 1 diabetes, multiple sclerosis, Parkinson’s disease, Wegener’s disease, collagen-vascular diseases such as rheumatoid arthritis, and Alzheimer’s disease.
The Frequency Research Foundation’s Clinical Experience
The Frequency Research Foundation has been identifying and developing frequencies for pathogenic mycoplasma since 2001. In over two decades of clinical observation, we have consistently found mycoplasma infections in a high percentage of chronically ill individuals — particularly those presenting with persistent Lyme disease, chronic fatigue, unexplained cognitive decline, and treatment-resistant cases.
Our companion articles cover additional dimensions of the mycoplasma problem: Mycoplasma Pneumoniae and Other Mycoplasmas provides an overview of the various species and their systemic effects, while Mycoplasma: A Key Component in Lyme and Other Diseases examines mycoplasma’s role as the critical co-infection that complicates recovery from Lyme and other chronic conditions.
Mycoplasma and the Brain: The Alzheimer’s Connection
The connection between mycoplasma and neurodegenerative disease is directly relevant to our Alzheimer’s research.
How Mycoplasma Damage the Brain
Mycoplasma can cross the blood-brain barrier — a critical distinction that separates them from many other pathogens. Once inside the brain, they trigger chronic microglial activation and neuroinflammation. This is the same persistent inflammatory state that drives Alzheimer’s disease progression.
The brain damage from mycoplasma operates through several mechanisms. Direct neuroinflammation from the immune system’s chronic attempt to fight an infection it cannot clear. Energy depletion of neurons through parasitic attachment. Disruption of neurotransmitter metabolism. Promotion of oxidative stress that damages neuronal membranes and DNA.
This means that for some people, chronic mycoplasma infection may be a contributing factor — or even a primary driver — of cognitive decline and neurodegenerative disease. Eliminating mycoplasma is therefore not just a Lyme disease issue. It is a brain health issue.
Our complete guide to Alzheimer’s disease and frequency therapy covers the full range of infections linked to Alzheimer’s, including not only mycoplasma but also herpes simplex virus — which has been found in 90% of Alzheimer’s plaques, as documented in our article Alzheimer’s and Herpes Simplex Virus.
2026 Update: What Has Advanced Since 2008
Since this article was first published, several important developments have occurred in mycoplasma research and treatment.
Improved Detection Methods
Mycoplasma detection has improved significantly. Advanced PCR-based testing can now identify multiple mycoplasma species with greater sensitivity than was available in 2008. This has led to increased recognition of mycoplasma’s role in chronic illness, though mainstream medicine still underdiagnoses these infections dramatically.
The Chronic Infection-Neurodegeneration Link Is Established
What was still emerging in 2008 is now well-established: chronic infections, including mycoplasma, are recognized contributors to neurodegeneration and cognitive decline. The broader “infectious theory of Alzheimer’s” has gained significant scientific support, with multiple pathogen types — viruses, bacteria, and mycoplasma — all implicated in driving the neuroinflammatory cascade that produces Alzheimer’s pathology.
Frequency Protocol Advancement
The Frequency Research Foundation’s mycoplasma frequency protocols have been significantly refined since 2008. Dr. Jeff Sutherland’s systematic approach to disassembling mycoplasma — targeting various structural components and dispersing DNA — has been developed through years of iterative testing and clinical observation. The protocols now address a wider range of mycoplasma strains and account for the co-infections (including nanobacteria) that complicate treatment.
Our [Lyme disease frequency protocol, Version 11.0](INSERT LYME V11 URL) represents the latest evolution of our comprehensive approach to the Lyme complex, including its mycoplasma components.
Post-COVID Relevance
The COVID-19 pandemic created millions of people with persistent symptoms — long COVID — that closely mirror chronic Lyme and mycoplasma infection: fatigue, brain fog, immune dysfunction, and chronic inflammation. This has brought mainstream attention to the concept of post-infectious chronic illness and has made the medical community more receptive to the idea that persistent organisms can drive ongoing symptoms long after the initial infection.
How Frequency Therapy Addresses Mycoplasma
Mycoplasma’s lack of a cell wall, which makes it resistant to most antibiotics, does not protect it from electromagnetic frequencies. Frequency therapy offers a fundamentally different mechanism of action that bypasses the cell wall entirely.
The Frequency Approach to Mycoplasma
Dr. Jeff Sutherland’s approach to mycoplasma involves a systematic, multi-stage process. Targeted frequencies address the mycoplasma organism directly, disrupting its structural integrity despite the absence of a cell wall. Sequential treatment addresses the nanobacteria that mycoplasma harbor internally, managing the Herxheimer reactions that occur as these secondary organisms are released. Strain-specific frequencies address the multiple mycoplasma species present in the Lyme complex. Supporting frequencies address the immune dysfunction and energy depletion that mycoplasma cause.
This systematic approach is necessary because mycoplasma infections are not simple, single-organism problems. They involve multiple strains, internal co-infections, and layered immune dysfunction that must be addressed in the right sequence.
Why Frequency Therapy Has an Advantage
Conventional antibiotics that work against mycoplasma — primarily tetracyclines and macrolides — require long treatment courses (often months), come with significant side effects, and have incomplete efficacy because mycoplasma can hide inside host cells where antibiotic concentrations may be subtherapeutic.
Frequency therapy is not limited by cell wall targeting, does not require months-long courses, can address organisms inside host cells, and can target multiple strains and co-infections within the same treatment framework.
Dealing with chronic Lyme, persistent fatigue, or unexplained cognitive symptoms? Mycoplasma co-infections may be the missing piece. Dr. Jeff Sutherland offers personalized paid consultations to identify the specific organisms driving your symptoms and develop a targeted frequency protocol. Book Your Consultation
Frequently Asked Questions
Take the Next Step
If you have been dealing with chronic Lyme disease, persistent fatigue, ongoing sinus problems, or unexplained cognitive decline, mycoplasma co-infections may be the underlying reason your symptoms continue despite treatment.
Dr. Jeff Sutherland has spent over two decades developing frequency protocols specifically for mycoplasma and the complex infections that accompany them. A paid consultation is the most direct way to assess whether mycoplasma is a factor in your case and develop a targeted treatment plan.
Book Your Consultation with Dr. Jeff Sutherland
This article is part of our comprehensive Alzheimer’s resource library. Mycoplasma infections that cross the blood-brain barrier contribute to the neuroinflammation that drives Alzheimer’s disease. Read our complete guide to Alzheimer’s disease and frequency therapy for the full scope of research on infections, environmental toxins, nutrition, and frequency-based treatment approaches.
© Frequency Research Foundation. This content is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult with qualified healthcare professionals regarding medical conditions.